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Abstract
Receptive anal intercourse (RAI) carries a greater per-act risk of HIV acquisition than receptive vaginal intercourse (RVI) 
and may influence HIV epidemics driven by heterosexual sex. This systematic review explores the association between 
RAI and incident HIV among women, globally. We searched Embase and Medline through September 2018 for longitudi-
nal studies reporting crude (cRR) or adjusted (aRR) relative risks of HIV acquisition by RAI practice among women. Of 
27,563 articles identified, 17 eligible studies were included. We pooled independent study estimates using random-effects 
models. Women reporting RAI were more likely to acquire HIV than women not reporting RAI (pooled cRR = 1.56 95% CI 
1.03–2.38, N = 18,  I2 = 72%; pooled aRR = 2.23, 1.01–4.92, N = 5,  I2 = 70%). In subgroup analyses the association was lower 
for women in Africa (pooled cRR = 1.16, N = 13,  I2 = 21%) than outside Africa (pooled cRR = 4.10, N = 5,  I2 = 79%) and 
for high-risk (pooled aRR = 1.69, N = 4,  I2 = 63%) than general-risk women (pooled aRR = 8.50, N = 1). Interview method 
slightly influenced cRR estimates (p value = 0.04). In leave-one-out sensitivity analyses pooled estimates were generally 
robust to removing individual study estimates. Main limitations included poor exposure definition, incomplete adjustment 
for confounders, particularly condom use, and use of non-confidential interview methods. More and better data are needed 
to explain differences in risk by world region and risk population. Women require better counselling and greater choice in 
prevention modalities that are effective during RVI and RAI.
Keywords Anal intercourse · HIV · Heterosexual · Women · Sexual behaviour · Meta-analysis
Introduction
HIV acquisition risk during one receptive anal intercourse 
(RAI) act unprotected by pre-exposure prophylaxis (PrEP) 
or condoms (URAI) is higher than during receptive vaginal 
intercourse (RVI) unprotected by PrEP or condoms (URVI), 
with pooled estimates from previous systematic reviews of 
1.25% (95% confidence interval (CI) 0.55–2.23) and 0.08% 
(0.06–0.11) per URAI and URVI act, respectively [1–3]. 
Heterosexual URAI practice could increase HIV incidence 
among women and impact HIV spread at the population-
level if practised sufficiently often by a sufficient fraction of 
women [4]. Current evidence from three systematic reviews Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1046 1-019-02651 -0) contains 
supplementary material, which is available to authorized users.
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among young women, South African women, and female sex 
workers (FSWs) suggests that RAI is common, with pooled 
estimates of the proportions practising RAI ranging from 
12 to 21% in the past 3 months and from 15 to 22% in their 
lifetimes across these three risk populations [5–7]. Although 
scarcer and more heterogeneous, data on the frequency of 
anal intercourse suggest that 2–16% of all sex acts among 
all women in these different risk populations are RAI [6, 7].
Mathematical modelling studies suggest that given the 
elevated per-act HIV risk, HIV incidence among women 
who practise RAI for a period of time, even if infrequently, 
could be substantially higher than among women who do 
not [4, 8], with obvious implications for HIV spread and 
HIV prevention [9, 10]. For example, a risk equation model 
among high-risk women from 20 US cities estimated that 
38% of HIV infections were due to RAI [11]. Another mod-
elling analysis in Papua New Guinea predicted that if 20% 
of all women practised RAI in 10% of sex acts, and 90% of 
RAI acts were condomless, the total number of new infec-
tions would be 40% greater than if only RVI occurred [8].
However, empirical estimates from longitudinal studies 
have found mixed results with, for example, studies report-
ing HIV incidences 3.5 times greater among women report-
ing RAI [12], 6.4 times greater among women reporting 
URAI [13], or reporting no statistical association [14, 15]. 
To date, no studies have systematically reviewed the pub-
lished evidence of an association between RAI or URAI 
and HIV incidence among women from longitudinal studies.
We aimed to (1) conduct the first systematic review of 
longitudinal studies reporting the association between RAI 
and HIV incidence among women globally, (2) produce 
pooled estimates of this association, (3) explore potential 
sources of heterogeneity across study estimates, and (4) test 
the robustness of pooled estimates to single study estimates.
Methods
This systematic review and meta-analysis was conducted in 
accordance with MOOSE and PRISMA guidelines [16, 17].
Search Strategy and Selection Criteria
We searched for longitudinal studies reporting estimates, 
or sufficient data to derive them, of the association between 
RAI over various recall periods and incident HIV, among 
women. Ovid Embase and Medline were searched for arti-
cles published between 1st January 1980 and 3rd September 
2018 using terms for longitudinal study designs, women, 
sexual behaviour and HIV (see Supplementary Material 
for full search terms). Full-text articles were retrieved if 
abstracts reported heterosexual sexual behaviour and HIV 
and were screened for estimates of the association between 
RAI and incident HIV, and non-English articles were 
excluded. Reports from randomised controlled trials (RCTs), 
cohort studies and serodiscordant couple studies were 
included. We excluded cross-sectional studies, case–con-
trol studies, and reviews. Bibliographies of relevant articles 
were examined for additional references. Authors were also 
contacted for additional estimates (see Supplementary Mate-
rial for details).
We extracted crude and adjusted estimates, or the nec-
essary data to derive estimates (details in Supplementary 
Material) of the relative risk (RR) of the association between 
RAI exposure and HIV incidence, which was measured dif-
ferently across studies. Studies either reported hazard rate 
ratios (HRR), incidence rate ratios (IRR), cumulative inci-
dence ratios (CIR), or odds ratios (OR) of the RAI-HIV 
association. These different measures can produce slightly 
different estimates of the magnitude of the association under 
specific conditions. HRR (derived from survival analysis 
models) and IRR (based on HIV incidence per person-year) 
are expected to produce similar estimates [18]. However, 
CIR, OR, and HRR/IRR based estimates may differ if HIV 
incidence is high, follow-up duration is long, or if the mag-
nitude of the association is large [19, 20]. Thus, to maxim-
ise uniformity across studies, HRR and IRR were extracted 
preferentially to CIR and OR, when available. When crude 
IRR was not directly reported but could be derived from the 
available data, derived crude IRR estimates were included 
preferentially to reported or derived CIR and OR. Crude 
HRR and adjusted HRR, IRR, CIR and OR could not be 
derived from published information. In situations where it 
was not possible to include HRR/IRR estimates, we included 
reported or derived CIR or OR estimates in order to max-
imise the number of included study estimates and assessed 
the influence of the type of measure on pooled estimates in 
subgroup analysis as described below.
Information on participant characteristics (e.g. world 
region, risk population, the percentage of study participants 
reporting RAI (the RAI prevalence), the frequency/number 
of RAI acts, antiretroviral treatment (ART) use by partner), 
study characteristics (e.g. study years, the recall period of 
RAI, definition of RAI) and study quality indicators (e.g. 
study design, interview method, whether the RR estimate 
was directly reported or self-calculated) was also extracted.
If multiple articles reported on the same study, the 
estimate from the largest sample was included. If articles 
reported multiple estimates from independent samples, all 
were included. If articles reported multiple estimates for 
smaller subgroups of a single sample, the combined estimate 
or largest subgroup was included. Both trial arms of RCTs 
were combined into a single group, provided the treatment 
had no significant effect in the original study, otherwise only 
the placebo group was included.
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Data Analysis
From this point onwards, we use the term “relative risk” 
(RR) to generically refer to the different measures of associ-
ation (HRR, IRR, CIR and OR). Independent study estimates 
of crude (cRR) and adjusted (aRR) relative risks and 95% 
CIs were log-transformed and pooled using DerSimonian-
Laird random-effects models based on inverse-variance [21]. 
To maintain uniformity, the 95% CIs of all study estimates 
were recalculated based on the normal approximation before 
pooling. Pooled estimates and 95% CIs were then exponen-
tiated back to give estimates on the original scale, which 
were displayed on forest plots. Heterogeneity across study 
estimates was assessed using  I2 statistics [22].
Potential sources of heterogeneity due to participant 
and study characteristics, type of measure of association 
(HRR, IRR, OR, CIR), and study quality indicators were 
explored in subgroup analyses on all variables and differ-
ences between subgroups were tested using Wald-type tests. 
In addition, we attributed scores reflecting study quality to 
each study estimate based on the Newcastle–Ottawa Scale 
(NOS) that varied from 0 to 9 points for estimates based 
on the lowest to highest quality studies, respectively [23]. 
Subgroup analysis was also used to explore publication bias 
stratifying by the location in the article where RAI was first 
mentioned (title/abstract, text/table) as studies may more 
prominently report stronger associations, and by whether 
RR estimates were self-derived or retrieved from contacted 
authors, as studies may not report estimates showing no 
effect. Publication bias was further assessed using funnel 
plots. Leave-one-out sensitivity analyses were conducted to 
assess how each study estimate influenced pooled estimates.
All analyses were conducted, and figures made, in R ver-
sion 3.4.5 using the “metafor” package [24, 25].
Results
Search Results
Database searches identified 27,563 titles, and 17,934 were 
screened after removing duplicates, resulting in 554 arti-
cles that went to full-text review (Fig. 1). Full-text review 
identified 19 articles and two further articles [12, 14] were 
identified through scanning bibliographies, giving a total 
of 21 included articles that reported on 17 unique longi-
tudinal studies. Additionally, 18 authors were contacted, 
and one provided a single cRR estimate. None were able to 
provide further aRR estimates. In total, 16 studies reporting 
18 independent cRR estimates (or sufficient data to derive 
estimates), including one study reporting three independent 
estimates, and five studies reporting five independent aRR 
estimates were included in the meta-analysis (Fig. 1). Two of 
the 21 articles were excluded from the analysis because they 
reported cRR and aRR estimates already reported in other 
articles [26, 27]. Four studies reported both cRR and aRR, 
12 studies reported only cRR, and one study reported only 
aRR. Five of the 12 studies reporting only cRR estimates 
also conducted multivariate analyses but did not include RAI 
in the model.
Study Characteristics
The main characteristics of the 17 studies included in the 
meta-analysis are presented in Table 1 (see Table S1 for 
additional details on included studies). Most studies were 
conducted in Africa (number of studies  [Ns] = 12) [12, 14, 
15, 28–37] after ART was introduced in 1996  (Ns = 11) 
[13–15, 28–34, 36, 37], and the most common study design 
was cohort  (Ns = 9) [28, 29, 31, 34–39], then RCT  (Ns = 6) 
[12–15, 30, 32, 33], and serodiscordant couple studies 
 (Ns = 2) [40–42]. Most studies were among high-risk women 
 (Ns = 11), including FSWs  (Ns = 6) [12, 14, 29, 31, 35, 37, 
38], and other high-risk populations  (Ns = 5) [13, 32, 33, 
40–42] such as serodiscordant couples (SDCs) and high-
risk HIV-negative women and the mean or median age in 
most studies was less than 28 years  (Ns = 10) [12, 13, 28, 
29, 32, 33, 35–37, 40, 41]. Study sample sizes varied hugely, 
ranging from 73 to 8859 women, and length of follow-up 
ranged from 258 to 8024 person-years  (Ns = 15). Almost 
all studies recorded sexual behaviour data, including RAI, 
in face-to-face-interviews (FTFI)  (Ns = 16) [12–15, 28–33, 
35–42] and only one [34] (which reported three independ-
ent estimates) used audio computer-assisted self-interviews 
(ACASI) [43]. RAI was most commonly measured during 
follow-up  (Ns = 10) [12, 15, 29, 30, 33, 34, 38–42] in the 
past 1 month  (Ns = 4) [12, 29, 30], 3 months  (Ns = 4) [15, 
33, 34, 38], 6 months  (Ns = 2) [40–42] and past year  (Ns = 1) 
[39], and only four of these studies analysed RAI as a time-
varying covariate [33, 34, 38, 42]. RAI was also measured at 
baseline  (Ns = 7) [13, 14, 28, 31, 32, 35–37], ‘ever’  (Ns = 4) 
[13, 31, 35, 36] and in the past 1 month  (Ns = 2) [28, 32]. 
Two articles reporting on the same study did not report the 
time frame of baseline RAI practise [14, 37]. Lifetime RAI 
prevalence ranged from 2 to 43%. RAI prevalence in the 
past 6 months ranged from 7 to 16%, 3 months from 2 to 
15%, and 1 month from 2 to 42%. Most studies first men-
tioned RAI in the main text  (Ns = 13) [12, 14, 15, 28, 30–38, 
42], with five mentioning it first in the abstract or title [13, 
29, 39–41]. No studies reported RAI frequency data. Two 
studies reporting only cRRs defined exposure as URAI only 
[13, 15]. A third study [41] controlled for condom use by 
dividing women into subgroups that ‘always’ or ‘sometimes/
never’ used condoms for all sex acts, reporting a cRR esti-
mate for the ‘sometimes/never’ subgroup only, as no sero-
conversions occurred in the ‘always’ subgroup. All other 
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studies either specified inconsistent condom use during RAI 
or did not specify condom use. No included studies reported 
estimates of partner ART use.
Most studies reported HRR (number of estimates 
 [Ne] = 7), then IRR  (Ne = 6), CIR  (Ne = 4), and OR  (Ne = 1). 
Three crude IRR, three crude CIR, and their 95% CIs were 
self-derived. All five adjusted estimates were HRR. Two 
were adjusted for age only [33, 36] and one for herpes 
simplex virus-2 (HSV-2) infection only [37]. The remain-
ing two were adjusted for age, sexual behaviour, sexually 
transmitted infections (STIs) [31]; and for condom use, 
symptoms of HIV/AIDS-related disease in the partner 
living with HIV, and ART use by the partner living with 
HIV [42]. One study reported a single crude HRR com-
bining data from four microbicide trials conducted in nine 
sites in Africa and one site in India [32], and was therefore 
included as an African estimate in subgroup analyses.
All estimates received a NOS score between 5 and 8, 
with 6 the most common score  (Ne = 13) [13, 15, 28, 30, 
32, 33, 35–41], indicating most studies were of adequate 
quality (Table S2). Across all estimates the most com-
monly failed criteria was ascertainment of exposure using 
FTFI rather than more confidential methods. For cRR, 
failure to adjust for potential confounders and for aRR, 
Fig. 1  Study selection. The 
search identified 21 articles for 
inclusion in the meta-analysis 
reporting on 17 independent 
studies that provided crude and/
or adjusted estimates of the 
relative risk of HIV acquisi-
tion associated with RAI 
among women. The search was 
conducted for articles published 
1st January 1980 up to the 3rd 
September 2018
17,934 identified for screening 
after duplicates removed
1,488 abstracts screened
16,446 excluded
by title
554 full-text 
articles reviewed 
in-depth 535 full-text articles excluded
336 insufficient RAI 
data
66 no HIV incidence 
data
47 abstract only
37 not longitudinal
18 not English
9 mathematical 
modelling studies
8 no seroconversions
6 reviews
5 no data for women 
only
3 HIV+ women only
17 studies (21 articles) 
included in quantitative 
synthesis (meta-
analysis)
27,563 potentially eligible studies 
identified by database search 
934 excluded by 
abstract
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failure to adjust for important confounders including con-
dom use, produced lower scores. Only one aRR estimate 
was adjusted for condom use.
Does RAI Practise Increase the Risk of HIV 
Acquisition Among Women?
The meta-analysis included 18 independent cRR estimates 
ranging from 0.45 to 24.3 across a total of 31,712 women 
(Fig. 2a), and five independent aRR estimates ranging from 
0.82 to 8.50 across a total of 2176 women (Fig. 2b). Despite 
substantial heterogeneity across estimates, the pooled cRR 
(1.56, 95% CI 1.03–2.38,  I2 = 72%, N = 18) and aRR (2.23, 
95% CI 1.01–4.92,  I2 = 70%, N = 5) suggested significantly 
higher HIV incidence rates among women reporting RAI 
(Fig. 2).
In the subset of four studies reporting both crude and 
adjusted estimates, the individual cRR and aRR estimates did 
not differ hugely (average difference = 39%) and the pooled 
cRR and aRR were of similar magnitude (pooled cRR = 1.26, 
95% CI 0.57–2.80, N = 4; pooled aRR = 1.69, 95% CI 
0.82–3.47, N = 4) (Fig. S1) to the overall pooled estimates 
based on all study estimates.
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Fig. 2  Forest plot of crude and adjusted study and pooled estimates. 
Crude (cRR, blue) and adjusted (aRR, red) study estimates of rela-
tive risk (squares), and corresponding pooled estimates (diamonds) of 
the association between HIV incidence and receptive anal intercourse 
(RAI) among women are given overall and stratified by world region. 
The dotted vertical line represents a relative risk of 1 (i.e. no effect of 
RAI on HIV incidence) (Color figure online)
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Subgroup Analysis
How Do Characteristics of the Study Participants Influence 
the RR?
In subgroup analyses, crude study estimates varied by world 
region (p = 0.03) with higher pooled estimates for studies 
outside Africa (pooled = 4.10, 95% CI 1.36–12.3,  Ne = 5, 
 I2 = 79%) than in Africa (pooled = 1.16, 95% CI 0.88–1.54, 
 Ne = 13,  I2 = 21%) (Fig. 2a, Table 2a). The small number of 
studies limited exploration of the heterogeneity across adjusted 
study estimates. Pooled aRR did not differ by world region 
(p = 0.90) but differed slightly (although non-significantly) by 
risk populations (p = 0.06) (Fig. 2, Table S3), with the pooled 
aRR for general-risk women higher (pooled = 8.50, 95% CI 
1.90–38.0,  Ne = 1) than for high-risk women (pooled = 1.69, 
95% CI 0.82–3.47,  Ne = 3,  I2 = 63%) (Table S3). Pooled cRR 
and aRR did not differ significantly by other participant char-
acteristics, including mean age or RAI prevalence.
How Do Study Characteristics and Study Quality Influence 
the RR?
In subgroup analysis, pooled cRR only differed significantly 
by interview method (p = 0.04), with lower estimates in stud-
ies using ACASI (pooled = 0.88, 95% CI 0.54–1.43,  Ne = 3, 
 I2 = 0%) than FTFI (pooled = 1.81, 95% CI 1.11–2.94, 
 Ne = 15,  I2 = 73%) (Table 2b). Pooled cRR and aRR did not 
differ by other study characteristics or quality indicators, 
including study year, study design, measurement of expo-
sure, definition of RAI, type of measure, and NOS score. 
In exploring potential publication bias, pooled cRR from 
study estimates directly reported in the original studies was 
slightly higher than when self-derived or retrieved from 
authors and from studies that more prominently reported 
RAI in the abstract or title rather than the main text 
(Table 2b). However, these differences were not statistically 
significant (Table 2b). Similar analyses could not be done 
for aRR estimates. Funnel plots also showed no evidence of 
publication bias across cRR estimates (Fig. S2A), but some 
evidence across aRR estimates (Fig. S2B).
How Do Individual Study Estimates Influence Pooled 
Estimates?
In leave-one-out sensitivity analyses, the direction of the 
associations remained intact (Fig. S3A–C). Overall, the 
pooled cRR estimate was mainly influenced by Novak’s 
[13] estimate among women in the US, one of the two stud-
ies defining RAI as URAI only (Fig. S3A). Omitting this 
estimate slightly lowered the pooled cRR and reduced the 
 I2 value (pooled without Novak = 1.30, 95% CI 0.95–1.77, 
 I2 = 42%) (Fig. S3A). Consistent with the low heterogeneity 
across study estimates, the pooled cRR for African studies 
was not influenced by any specific estimate (Fig. S3B). The 
overall pooled aRR was equally sensitive to most study esti-
mates, which slightly influenced results in either direction, 
although omission of Ramjee substantially reduced the  I2 
value  (I2 = 34%) (Fig. S3C).
Discussion
Our review and meta-analysis of published longitudinal 
studies provides new knowledge on a key HIV acquisition 
risk among women who have sex with men. Overall, HIV 
incidence was approximately twice as high (pooled crude 
RR = 1.56, pooled adjusted RR = 2.23) among women 
reporting RAI than women reporting RVI only. Since 
women do not typically practise RAI in all sex acts, our 
pooled estimate is consistent with current evidence suggest-
ing that HIV risk per URAI act is up to 10–20 times higher 
than per URVI act [1–3].
Our results also suggested a more modest RAI-HIV asso-
ciation for higher-risk populations and women in Africa, 
but more data are needed to fully explain these differences. 
Additionally, although our analysis suggested slight differ-
ences by world region, interview method, and risk popula-
tion, all confidence intervals were wide and overlapping. 
Nonetheless, our results have implications for understanding 
HIV spread, identifying HIV interventions needs, and devel-
oping more HIV prevention modalities effective during both 
RVI and RAI [10, 44, 45].
To our knowledge, this is the first systematic review 
and meta-analysis on the increased risk of HIV acquisition 
through RAI compared to RVI among heterosexual women 
from longitudinal studies only and our study has several 
strengths that improve the generalisability and robustness 
of our findings. We used broad search terms to maximise 
coverage and restricted inclusion to longitudinal studies, 
ensuring that timings of RAI exposure and HIV acquisi-
tion were more precisely ascertained. We limited reporting 
and publication biases by deriving estimates which were not 
explicitly reported in publications and by contacting authors 
for additional estimates. Furthermore, we systematically 
extracted information on study and participant character-
istics and conducted comprehensive subgroup and sensitiv-
ity analyses to identify potential sources of heterogeneity, 
explore the influence of study quality on pooled estimates, 
and assess the robustness of our results.
Although we sought additional estimates from authors, 
our analysis was limited to information available from the 
included studies. Studies reported different measures of 
association, which may have influenced results [46], how-
ever there were no statistical differences between HRR, IRR, 
CIR, or OR-based estimates. Most studies only reported 
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Table 2  Subgroup analyses of crude study estimates (cRR) stratified by participant and study characteristics and quality indicators
ACASI Audio computer-assisted self-interview, CI confidence interval, CIR cumulative incidence ratio, cRR crude relative risk, FTFI face-to-
face interview, IRR incidence rate ratio, HRR hazard rate ratio, Ne number of estimates, NOS Newcastle–Ottawa Scale, NR not reported, OR odds 
ratio, RAI receptive anal intercourse, RCT randomised controlled trial, URAI unprotected (condomless and no PrEP) receptive anal intercourse
Continuous variables were dichotomised at the median, except for study year, which was dichotomised at the boundary between the pre-, and 
post-antiretroviral treatment (ART) eras (1996). Statistically significant p-values are given in bold
a Study year is the midpoint between study start and finish
Variable Ne References Pooled cRR 95% CI p value I2 (%)
a. Participant characteristics
 World region 0.03
  Africa 13 [12, 14, 15, 28–35] 1.16 0.88–1.54 – 21
  Out of Africa 5 [13, 38–41] 4.10 1.36–12.3 – 79
 Risk population 0.27
  General-risk 7 [15, 28, 30, 34, 41] 1.22 0.84–1.78 – 22
  High-risk 11 [12–14, 29, 31–33, 35, 38–40] 1.85 0.97–3.51 – 79
 Mean age (missing = 6) 0.76
  ≤ 28 6 [29, 32, 33, 35, 39, 40] 1.14 0.77–1.69 – 2
  > 28 6 [14, 15, 31, 34] 1.05 0.73–1.50 – 20
 RAI prevalence (missing = 3) 0.14
  ≤ 14% 8 [12, 13, 15, 28, 30, 34, 39] 1.77 0.91–3.44 – 81
  > 14% 7 [14, 29, 31, 34, 35, 40, 41] 0.96 0.62–1.49 – 29
b. Study characteristics and quality indicators
 Study  yeara 0.32
  Pre-1996 6 [35, 38–41] 2.30 0.96–5.48 – 69
  1996 onwards 12 [12–15, 28–34] 1.37 0.83–2.27 – 75
 Study design 0.50
  Cohort 9 [28, 29, 31, 34, 35, 38, 41] 1.20 0.70–2.05 – 52
  RCT 7 [12–15, 30, 32, 33] 2.05 1.03–4.10 – 81
  Serodiscordant couple 2 [39, 40] 1.25 0.65–2.43 – 0
 Interview method 0.04
  ACASI 3 [34] 0.88 0.54–1.43 – 0
  FTFI 15 [12–15, 28–33, 35, 38–41] 1.81 1.11–2.94 – 73
 Measurement of  exposureb 0.73
  Baseline: short time frame 2 [28, 32] 1.34 0.62–2.88 – 0
  Baseline: long time frame 3 [13, 31, 35] 2.00 0.52–7.67 – 92
  During follow-up: anytime 7 [12, 15, 29, 30, 39–41] 1.58 1.09–2.29 – 10
  During follow-up: time-varying 5 [33, 35, 38] 1.70 0.68–4.26 – 69
  Unclear 1 [14] 0.53 0.22–1.29 – –
 Definition of RAI 0.17 –
  URAI only 2 [13, 15] 3.29 0.88–12.4 – 91
  Any RAI 16 [12, 14, 28–35, 38–41] 1.27 0.90–1.79 – 43
 Type of measure 0.38
  HRR 8 [14, 32–34, 38] 1.28 0.75–2.20 – 58
  IRR 5 [12, 29, 30, 39, 40] 1.45 0.96–2.19 – 0
  CIR 4 [13, 15, 28, 35] 1.77 0.58–5.36 – 89
  OR 1 [41] 19.8 1.25–314 – –
 Extraction of estimate 0.53
  Directly reported 13 [12–14, 29, 31, 32, 34, 38–41] 1.67 0.94–2.96 – 77
  Self-calculated/from authors 5 [15, 28, 30, 33, 35] 1.32 0.85–2.05 – 28
 Location RAI first reported 0.32
  Title/abstract 5 [13, 29, 39–41] 2.33 0.76–7.09 – 79
  Text/table 13 [12, 14, 15, 28, 30–35, 38] 1.29 0.91–1.82 – 47
 NOS score 0.33
  5 5 [12, 13, 29, 31, 33] 1.42 0.59–3.38 – 59
  6 10 [13, 15, 28, 30, 32, 35, 38–41] 2.01 1.11–3.64 – 78
  7 3 [34] 0.88 0.54–1.43 – 0
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crude estimates without adjusting for potential confound-
ers and none of the eight authors of these studies that were 
contacted provided adjusted estimates, meaning the HIV-
RAI association may be over- or underestimated. Potential 
for unmeasured or residual sources of confounding such as 
ART use and other partner characteristics cannot be totally 
ruled out even in adjusted analysis [47, 48]. Additionally, 
there was some evidence from funnel plots of publication 
bias toward higher aRR study estimates, suggesting authors 
may have been more likely to include RAI in multivariate 
models if the RAI-HIV association was high. Nevertheless, 
the overall pooled cRR estimate was similar, albeit slightly 
lower, than overall pooled aRR in both the full dataset and 
the subset of four studies reporting both cRR and aRR, and 
within these studies individual cRRs and aRRs did not differ 
substantially. This suggests the pooled cRR may somewhat 
underestimate the association but that inclusion of aRRs 
from studies that only provided cRRs would not have sub-
stantially influenced the pooled aRR. Despite substantial 
heterogeneity across both cRR and aRR study estimates, 
our overall pooled estimates were fairly robust since the 
direction and magnitude of association were not particularly 
influenced by any study estimate in our leave-one-out sensi-
tivity analysis, although pooled aRR were more sensitive to 
individual study estimates partly due to the smaller number 
of estimates available.
Our subgroup analysis of crude and adjusted estimates 
highlighted potential differences in the magnitude of the 
RAI-HIV association by world region and risk popula-
tion, respectively. Pooled estimates for the subset of studies 
conducted among women in sub-Saharan Africa (pooled 
cRR = 1.2) and among high-risk women (pooled aRR = 1.7) 
were lower than overall pooled estimates and non-statisti-
cally different than the null. As we did not find consistent 
patterns by both world region and risk population across 
estimates of both cRR and aRR in subgroup analysis, these 
differences may be real or due to methodological issues.
On the one hand, the low RAI-HIV association in high-
risk women may partly reflect their exposure to multiple 
competing risk factors such as high rates of STIs and genital 
ulcer diseases [49, 50], large numbers of commercial and/
or high-risk partners [51–53], differential levels of partner 
ART use [54], and differential frequencies of ejaculation 
by sex act [55], which may all increase the HIV acquisi-
tion risk during RVI and dilute the difference between RVI 
and RAI and were not properly accounted for in confounder 
analyses within the studies. Differences in ART use of 
sexual partners may explain variation in pooled estimates 
as evidence suggests that women practising condomless 
RAI are at a substantially reduced risk of HIV acquisition 
when their male sexual partners are taking suppressive ART 
[48]. However, this could not be explored as no included 
studies reported levels of partner ART use. Bias towards 
the null could also have occurred among high-risk women 
if they were more likely to use condoms during RAI than 
RVI, although evidence from reviews suggests condom use 
during RAI is as much as or slightly less than during RVI 
[6, 7]. Our pooled cRR for the only two studies reporting 
URAI only was higher (pooled cRR = 3.3) than for studies 
reporting any RAI (pooled cRR = 1.3), thus overall pooled 
estimates of the HIV-RAI association following exposure 
to URAI may be higher than our current pooled estimates 
for RAI. It was therefore surprising that only one aRR esti-
mate was adjusted for condom use. We could not further 
explore URAI for adjusted estimates as none were based 
on URAI. Differences in RAI frequency among study par-
ticipants may also explain variation in the magnitude of the 
RAI-HIV association by world region and risk populations 
[44], however this could not be investigated as no included 
studies reported RAI frequency.
On the other hand, exposure misclassification within 
original studies due to social desirability bias may explain 
regional variation in cRR estimates, since most studies 
recorded sexual behaviour data using FTFIs. RAI is highly 
stigmatised in many countries, particularly in sub-Saharan 
Africa, where it is also often misunderstood [56, 57]. For 
example, previous analyses of the ASPIRE and VOICE tri-
als in Sub-Saharan Africa have reported contrasting levels 
of RAI reporting by women with FTFI (2%) compared to 
ACASI (17%) [58, 59]. A systematic review of hetero-
sexual AI practice among South Africans similarly found 
higher reporting of lifetime AI with ACASI (pooled pro-
portion = 29%) than FTFI (pooled proportion = 3%) [6]. 
Counterintuitively, our pooled cRR of the HIV-RAI asso-
ciation from the single study (reporting three independent 
estimates) using ACASI was lower than from studies using 
FTFI, which may reflect the greater risk of misinterpreta-
tion with ACASI [57]. Discussion of RAI is particularly 
taboo in some cultures, with some local languages such as 
Zulu (South Africa) and Shona (Zimbabwe) having no word 
for RAI or instead referring to it in only euphemistic terms 
[57], meaning questions regarding RAI are more likely to 
be misinterpreted as meaning RVI, but in a different posi-
tion [57, 60, 61]. Therefore ACASI, although limiting social 
desirability bias, may not always more accurately estimate 
RAI than FTFI unless worded more carefully and pictorially. 
This could not be explored for adjusted estimates as none 
were based on ACASI.
b Short time frame includes RAI in the past 6 months or less, long time frame includes RAI in the past year to lifetime
Table 2  (continued)
678 AIDS and Behavior (2020) 24:667–681
1 3
Misclassification due to poor exposure definition was also 
possible [62, 63], and may have been more likely in studies 
defining RAI exposure at baseline and ever over a subject’s 
lifetime rather than exposure specifically during follow-up, 
as women reporting baseline RAI may not have practised 
it during follow-up [64]. Misclassification may also have 
occurred if ejaculation was not included in the RAI defini-
tion as women may not identify anal penetration without 
ejaculation as anal intercourse [65]. Additionally, since few 
studies reporting RAI during follow-up analysed it as time-
varying, misclassification may have occurred as most studies 
did not account for intermittent RAI practice and because 
defining a precise recall period that coincides with the exact 
HIV exposure period is challenging since it depends on the 
testing frequency and the window period of the test [66–68]. 
Nonetheless, we did not find any differences by measure-
ment of RAI in subgroup analysis.
Despite key limitations of original studies, including non-
confidential interview methods and the lack of adjustment 
for potential confounders, most studies scored highly on the 
NOS, however the small number of included studies lim-
ited our own analysis. Even though few characteristics were 
identified that significantly influenced results in univariate 
subgroup analysis, we were unable to conduct multivariate 
analysis to explore factors that could explain the differential 
association by world region or risk population. Therefore, 
it is unclear whether the differences are real or the result of 
ecological bias due to the same set of studies having differ-
ent characteristics.
Nonetheless, the findings of this review have public health 
implications for the prevention of HIV among women. The 
high cRR and aRR estimates from studies conducted before 
and after the introduction of ART in 1996 suggest that 
women who practise RAI remain at increased risk of HIV 
acquisition. RAI should no longer be neglected as a key risk 
factor and women should be provided with the means to 
prevent HIV acquisition through both RAI and RVI. This 
includes improving prevention messaging promoting con-
dom use and oral PrEP, which are effective during both RAI 
and RVI, and developing new prevention technologies. Oral 
PrEP has proved effective in reducing individual acquisition 
risk in placebo-controlled trials when used appropriately, 
however uptake and adherence in trials has been limited and 
outside of trial settings PrEP is not yet widely used [57, 69]. 
Microbicides provide an alternative method of prevention, 
however vaginal microbicides have shown limited efficacy 
and would not be effective during RAI [9, 58, 69–72]. Dual 
compartment rectal and vaginal products could provide an 
important solution to this problem and recent studies suggest 
vaginally administered products may be able to provide dual 
protection during both RAI and RVI. For example, recent 
studies of intravaginal rings and vaginally-administered 
gels have demonstrated rapid dissemination of tenofovir and 
emtricitabine from vaginal to rectal tissue [73–75]. The con-
tinued development of such products is important to meet 
the need for greater choice in prevention methods, so women 
at risk of HIV acquisition are able to protect themselves.
A frequent limitation of studies included in our review 
was the poor methods used to quantify RAI practice or cal-
culate RRs. It is surprising that after so many years and 
with the recognition of RAI as an important risk factor for 
HIV that RAI has not been more systematically investigated. 
Furthermore, with the knowledge that URAI is important for 
HIV transmission [3], the lack of data on URAI and condom 
use during RAI is disappointing. More longitudinal studies 
are urgently needed to evaluate whether the variation in RR 
by world region and risk population that we found is real and 
to provide further measures of RAI and condomless RAI. 
Such studies should define RAI more precisely including 
whether ejaculation occurred and test definitions to deter-
mine the extent to which women can report on ejaculation. 
They should standardise outcome measures to aid compara-
bility across studies, and take into account condom use and 
RAI frequency. They should routinely measure RAI at regu-
lar intervals when HIV testing and carefully define the recall 
period to maximise the chance that it corresponds with the 
HIV exposure period prior to HIV acquisition. They should 
include RAI as a time-varying covariate in survival analyses 
to estimate RRs, and where possible include RAI in multi-
variate models with other important risk factors including 
condom use. Finally, confidential interview methods such as 
ACASI should also be used to limit social desirability bias 
and questions about RAI should be clear and unambiguous, 
potentially making use of visual aids, to minimise misin-
terpretation and to produce more accurate estimates of RAI 
practice [76, 77].
Conclusions
In conclusion, women practising RAI may be at an increased 
risk of HIV acquisition, however there is some uncertainty 
in differences by region and risk population. Better data on 
RAI practice among women is necessary in order to answer 
the questions that this review has raised regarding variation 
in RAI-HIV risk by world region and risk population and to 
address gaps in the data surrounding the frequency of RAI 
and condom use during RAI. More prevention tools that 
provide dual protection against HIV acquisition during both 
RAI and RVI are needed, and women should be provided 
greater choice in prevention methods.
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